The impact of physical frailty on the response to inactivated influenza vaccine in older adults

Krissy K. Moehling\textsuperscript{1,2,*}, Bo Zhai\textsuperscript{3}, William E. Schwarzmann\textsuperscript{4}, Uma R. Chandran\textsuperscript{4}, Marianna Ortiz\textsuperscript{3}, Mary Patricia Nowalk\textsuperscript{5}, David Nace\textsuperscript{5}, Chyongchiou J. Lin\textsuperscript{1,6,*}, Michael Susick\textsuperscript{1}, Min Z. Levine\textsuperscript{7}, John F. Alcorn\textsuperscript{3}, Richard K. Zimmerman\textsuperscript{1}

\begin{itemize}
\item \textsuperscript{1}Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA
\item \textsuperscript{2}Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15213, USA
\item \textsuperscript{3}Division of Pulmonary Medicine, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15224, USA
\item \textsuperscript{4}Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15261, USA
\item \textsuperscript{5}Division of Geriatric Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
\item \textsuperscript{6}Ohio State University College of Nursing, Columbus, OH 43210, USA
\item \textsuperscript{7}National Center for Immunization and Respiratory Diseases, Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
\end{itemize}

*Completed work while at the Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA

Correspondence to: Richard K. Zimmerman; email: zimmrk@upmc.edu

Keywords: frailty, immune response, antibody titers, peripheral cell mediated immunity, influenza

Received: August 14, 2020       Accepted: October 27, 2020       Published: December 9, 2020

Copyright: © 2020 Moehling et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Physical frailty’s impact on hemagglutination inhibition antibody titers (HAI) and peripheral blood mononuclear cell (PBMC) transcriptional responses after influenza vaccination is unclear. Physical frailty was assessed using the 5-item Fried frailty phenotype in 168 community- and assisted-living adults ≥55 years of age during an observational study. Blood was drawn before, 3, 7, and 28 days post-vaccination with the 2017-2018 inactivated influenza vaccine. HAI response to the A/H1N1 strain was measured at Days 0 and 28 using seropositivity, seroconversion, log\textsubscript{2} HAI titers, and fold-rise in log\textsubscript{2} HAI titers. RNA sequencing of PBMCs from Days 0, 3 and 7 was measured in 28 participants and compared using pathway analyses. Frailty was not significantly associated with any HAI outcome in multivariable models. Compared with non-frail participants, frail participants expressed decreased cell proliferation, metabolism, antibody production, and interferon signaling genes. Conversely, frail participants showed elevated gene expression in IL-8 signaling, T-cell exhaustion, and oxidative stress pathways compared with non-frail participants. These results suggest that reduced effectiveness of influenza vaccine among older, frail individuals may be attributed to immunosenescence-related changes in PBMCs that are not reflected in antibody levels.

INTRODUCTION

The burden of influenza-related morbidity and mortality among older adults is substantial. Surveillance studies estimate that 71\%–85\% of influenza deaths occur in adults ≥65 years of age [1]. Adults ≥65 years are 10 to 30 times more likely than younger adults to experience acute respiratory failure attributed to influenza disease [2]. Other complications include higher rates of pneumonia, stroke and heart attack [3]. Low vaccine effectiveness among the elderly has been attributed to senescence of the immune system and a decreased immune response to vaccine antigens. Decreased humoral and cell-mediated immune responses have
been reported specific to influenza vaccination in older adults compared with younger adults [4], including altered T-cell function and overall declines in cell-mediated adaptive immunity [3].

Overlaid on age-related immunosenescence are the effects of frailty [4], a multi-dimensional syndrome marked by losses in function and physiological reserve [5]. Physical frailty, characterized by diminished strength, endurance, and reduced physiologic function [6], leads to increased risk of acute illness, falls, disability, hospitalization, institutionalization and mortality [5, 7].

Frailty’s impact upon older adults’ antibody immune response outcomes after influenza vaccination is unclear. A 2011 study found that physical frailty among community-dwelling adults >70 years of age was associated with diminished immunological response to influenza vaccine and more severe influenza-like illness [8]. More recent studies have found no difference in post-vaccination antibody titers between frail and non-frail or between frail and pre-frail community-dwelling older adults ≥65 years [9–12].

Efforts to develop more effective vaccines have driven research on humoral and cell-mediated immune responses to influenza virus. These studies [13–16] have focused on general subpopulations of older adults without consideration of factors that may directly affect the degree of immunosenescence, such as physical frailty. The purpose of this study was to assess hemagglutination inhibition antibody (HAI) titers and peripheral blood mononuclear cell (PBMC) transcriptomic responses to influenza vaccine in the context of physical frailty status.

**RESULTS**

**Demographics**

Characteristics for the entire cohort as well as by frailty status among the entire cohort and PBMC subgroup are presented in Table 1. Overall, participants were primarily female (68.5%) and white (76.2%). Forty-seven percent were taking a statin medication, 32.5% noted having ≥2 chronic health conditions, and 41.1% were obese. Median age was 71.5 years (64.9-83.1). Overall, frailty was low, with 34.5% of the cohort considered frail; frail persons had 2-4 “frailty components.” Frail individuals were significantly older (74.3 vs. 70.5 years; \( P = 0.040 \)), were more likely to have 1 or more high risk condition (\( P = 0.007 \)) and had lower ADL (13.0 vs. 14.0; \( P < 0.001 \)) and IADL (13.0 vs. 14.0; \( P < 0.001 \)) scores. Frail individuals in the PBMC subgroup were significantly older (82.9 vs. 67.5 years, \( P = 0.012 \)), had higher BMI (31.0 vs. 26.4, \( P = 0.045 \)), and as expected, scored lower on functional status measures (13.0 vs.14.0, \( P = 0.002 \) for ADL and 11.0 vs.14.0, \( P = 0.009 \) for IADL).

**HAI results**

Pre- and post-vaccination A/H1N1 HAI antibody titers of the entire cohort and for the PBMC subgroup by frailty status are reported in Table 2. Nearly half (47.6%) of the cohort was considered seropositive at Day 0 rising to 80.3% seropositivity at Day 28. Only 35.7% of the cohort seroconverted 28 days post-vaccination, with a mean fold-rise in the log_2 titer ratio of 1.44 ± 0.58 for the cohort. There were no significant differences between frailty subgroups in any HAI response outcome.

Multivariable regression was performed on data from the entire cohort to determine predictors of H1N1 antibody response. Frailty was not significantly associated with any Day 28 measure of HAI titers when adjusting for demographic factors. Day 0 log_2 HAI titer, age, and sex were significantly associated with seroprotection and seroconversion (Table 3). Younger age and being female were significantly related to higher Day 28 seropositivity and seroconversion.

**PBMC results - differentially expressed genes (DEG) between frail and non-frail groups at Days 0, 3 and 7**

Table 4 shows the DEGs that were significantly different between frail and non-frail groups at Days 0, 3 and 7. In total, there were 584, 597, and 776 DEGs at Day 0, 3, and 7, respectively. At all three time points, frail adults showed lower expression of genes in interferon signaling pathways, suggesting lower baseline interferon activation compared to the non-frail group. Several interferon-induced proteins, IFI16, IFTT1, IFTT3, IFITM3, MX1, and ISG15 were decreased in the frail adults. Of note, interferon-inducible transmembrane-1 (IFTT1), MX dynamin-like GTPase 1 (MX1), and interferon stimulated gene (ISG15) were down regulated > 1 log ratio at all three time points (Supplementary Table 1). Other pathways involved in vaccine responses, including activation of interferon regulatory factor, (IRF) by cytosolic pattern recognition receptors on Day 0, communication between innate and adaptive immune cells on Day 3, and B cell receptor signaling on Day 0 and Day 7, were decreased in the frail adults, suggesting reduced basal activation of both innate and adaptive immune responses.

IL-8 signaling was increased in the frail adults on Day 0 and Day 3, corroborating previous studies that increased IL-8 expression occurs in frailty and
Table 1. Demographics on entire cohort and subset analytic group by frailty status.

| Variables                                | Entire cohort (N=168) | Frail (N=58) | Non-frail* (N=110) | P value | PBMC subset Frail (N=13) | PBMC subset Non-frail (N=15) | P value |
|------------------------------------------|-----------------------|--------------|--------------------|---------|-------------------------|-------------------------------|---------|
| Age, yr, Median (Q1, Q3)                 | 71.5 (64.9,83.1)      | 73.4 (66.4,88.2) | 70.5 (63.3,81.0)   | 0.040   | 82.9 (72.7,88.1)        | 67.5 (62.9,72.9)              | 0.012   |
| Female sex, N (%)                        | 115 (68.5)            | 41 (70.7)    | 74 (67.3)          | 0.651   | 9 (69.2)                | 12 (80.0)                    | 0.670   |
| Caucasian race, N (%)                    | 128 (76.2)            | 46 (79.3)    | 82 (74.6)          | 0.491   | 12 (92.3)               | 14 (93.3)                    | 1.000   |
| Non-Hispanic, N (%)                      | 165 (98.2)            | 58 (100.0)   | 107 (97.3)         | 0.552   | 13 (100.0)              | 14 (93.3)                    | 1.000   |
| BMI Median (Q1, Q3)                      | 27.8 (24.5,33.1)      | 29.7 (24.4,35.1) | 27.4 (24.5,31.1)   | 0.075   | 31.0 (29.3,34.8)        | 26.5 (24.7,30.5)              | 0.045   |
| Current smoker, N (%)                    | 22 (13.1)             | 10 (17.2)    | 12 (10.9)          | 0.247   | 1 (7.7)                 | 1 (6.7)                      | 1.000   |
| 1 high-risk condition, N (%), ref. = 0   | 59 (36.2)             | 22 (37.9)    | 37 (35.2)          | 0.007   | 5 (38.5)                | 4 (28.6)                     | 0.555   |
| ≥ 2 high-risk conditions, N (%), ref. = 0| 53 (32.5)             | 26 (44.8)    | 27 (25.7)          |         | 6 (46.2)                | 5 (35.7)                     |         |
| Current statin medication use, N (%)     | 79 (47.0)             | 31 (53.5)    | 48 (43.6)          | 0.226   | 8 (61.5)                | 5 (33.3)                     | 0.255   |
| ADL score, median (Q1, Q3)               | 14.0 (13.0,14.0)      | 13.0 (13.0,14.0) | 14.0 (14.0,14.0)   | <0.001  | 13.0 (13.0,13.0)        | 14.0 (14.0,14.0)              | 0.002   |
| IADL score, median (Q1, Q3)              | 14.0 (13.0,14.0)      | 13.0 (8.0,14.0) | 14.0 (13.0,14.0)   | <0.001  | 11.0 (7.0,14.0)         | 14.0 (13.0,14.0)              | 0.009   |
| 0-1 Frailty components (non-frail), N (%)| 110 (65.5)            | -            | -                  |         | -                       | -                             | -       |
| ≥ 2 Frailty components (frail), N (%)    | 58 (34.5)             | -            | -                  |         | -                       | -                             | -       |

1 Chi-square/Fisher’s Exact for categorical variables, Wilcoxon for continuous variables.

2 Comorbidities include: diabetes, heart disease, asthma, chronic lung disease, blood disorders, kidney disorders, liver disease, neurological disorders, osteoporosis.

3 ADL and IADL, scores range from 0-14, higher scores indicate greater functionality.

Table 2. Pre- and post-vaccination A/H1N1/Michigan/45/2015-pdm09-like virus antibody titers.

| HAI response to A/H1N1 | Entire cohort (N=168) | Frail (N=58) | Non-frail* (N=110) | PBMC subset Frail (N=13) | PBMC subset Non-frail (N=15) | P value |
|------------------------|-----------------------|--------------|--------------------|-------------------------|-------------------------------|---------|
| Day 0 log2 HAI titer, Mean ± SD | 4.86 ± 1.87 | 4.70 ± 1.96 | 4.94 ± 1.83 | 3.78 ± 1.66 | 4.19 ± 1.81 |         |
| Day 28 log2 HAI titer, Mean ± SD | 6.31 ± 1.69 | 6.30 ± 1.75 | 6.32 ± 1.67 | 5.82 ± 1.34 | 5.89 ± 1.27 |         |
| Day 0 seropositivity rate, N (%) | 80 (47.6) | 24 (41.4) | 56 (50.9) | 3 (23.1) | 5 (33.3) |         |
| Day 28 seropositivity rate, N (%) | 135 (80.3) | 45 (77.6) | 90 (81.8) | 8 (61.5) | 12 (80.0) |         |
| Day 28 seroconversion rate, N (%) | 60 (35.7) | 21 (36.2) | 39 (35.5) | 5 (38.5) | 6 (40.0) |         |
| Day 28 fold-rise in log2 HAI titer, Mean ± SD | 1.44 ± 0.58 | 1.50 ± 0.64 | 1.41 ± 0.55 | 1.77 ± 0.81 | 1.59 ± 0.58 |         |

Seropositivity = HAI titer ≥40; Seroconversion (4-fold rise in post-vaccination titer at Day 28 given Day 0 titer ≥10).

1 All values for tests >0.05 for differences between frail and non-frail groups; Chi-square/Fisher’s Exact for categorical variables; t-test for continuous variables.

Table 3. Predictors of influenza A/H1N1/Michigan/45/2015-pdm09-like virus antibody titers from multivariable regression for entire cohort (N=168).

| Outcomes from logistic regression | OR (95% CI) | P value |
|----------------------------------|-------------|---------|
| A/H1N1 Day 28 Seropositivity (HAI titer ≥1:40) |            |         |
| Frail, ref.=non-frail            | 1.16 (0.45-2.97) | 0.754   |
| Age, years                       | 0.95 (0.91-0.99) | 0.008   |
| Female, ref.=male                | 2.84 (1.07-7.51) | 0.036   |
| A/H1N1 log2 Day 0 HAI titers     | 2.12 (1.54-2.92) | <0.001  |
| A/H1N1 Day 28 Seroconversion (4-fold rise) |            |         |
| Frail, ref.=non-frail            | 1.17 (0.54-2.54) | 0.698   |
| Age, years                       | 0.94 (0.91-0.98) | 0.002   |
| Female, ref.=male                | 2.76 (1.19-6.43) | 0.019   |
| A/H1N1 log2 Day 0 HAI titers     | 0.59 (0.47-0.74) | <0.001  |

| Outcomes from linear regression | Beta (SE) | P value |
|---------------------------------|-----------|---------|
|                                 |           |         |
**A/H1N1 Log2 Day 28 HAI titers**

| Frail, ref.=non-frail | 0.27 (0.22) | 0.233 |
|----------------------|-------------|-------|
| Age, years           | -0.03 (0.01)| 0.001 |
| A/H1N1 log2 Day 0 HAI titers | 0.51 (0.06) | <0.001 |

**A/H1N1 Log2 fold-rise in HAI titers (Day 28/Day 0)**

| Frail, ref.=non-frail | 0.05 (0.07) | 0.492 |
|----------------------|-------------|-------|
| A/H1N1 log2 Day 0 HAI titers | -0.20 (0.02) | <0.001 |

1A/H1N1=A/H1N1/Michigan/45/2015-pdm09-like virus.

---

**Table 4. Differentially expressed pathways between frail (N=13) and non-frail (N=15) individuals on Day 0 (pre-vaccination) and Days 3 and 7 post-vaccination analyzed by Ingenuity pathways analysis.**

| Ingenuity canonical pathways | Day 0 pre-vaccination | Day 3 post-vaccination | Day 7 post-vaccination |
|-----------------------------|------------------------|------------------------|------------------------|
| Activation of IRF by cytosolic pattern recognition receptors | | | |
| Upregulated genes | ADAR, DHX58, IFIT2, IRF7, IRF9, ISG15, STAT2, ZBP1 | | IFNAR1, DHX58, IFIT2, IKBKE, IRF7, ISG15, STAT2, ZBP1 |
| Downregulated genes | | | |
| B cell receptor signaling | RAP2A | FOXO1, IGHG2, IGHG3, IGHG4, PIK3CD, PRKCB, PTK2, RASSF5 | | |
| Communication between innate and adaptive immune cells | | CCR7, CD4, CD40LG, IGHG1, IGHG2, IGHG3, TNFRSF12B | | |
| EIF2 signaling | | | EIF1, Kras, PPP1CB, RAP2A, RPL36A | |
| Glutathione biosynthesis | GCLC | | GCLC, GCLM |
| GM-CSF signaling | | | |
| Heme biosynthesis II | CPOX, HMBS, UROS | | |
| HIF 1-alpha signaling | ELOB, MMP8, PDGFC, RAP2A, RBX1, SLC2A5 | | |

---

**Note:**

- The table lists differentially expressed pathways between frail and non-frail individuals on Day 0 (pre-vaccination) and Days 3 and 7 post-vaccination, analyzed using Ingenuity pathways analysis.
- The pathways include activation of IRF by cytosolic pattern recognition receptors, B cell receptor signaling, communication between innate and adaptive immune cells, EIF2 signaling, glutathione biosynthesis, GM-CSF signaling, heme biosynthesis II, and HIF 1-alpha signaling.
immunosenescence. Additionally, on Day 7 post-vaccination, several nuclear factors and signal transduction proteins shared by two pathways, regulation of IL-2 expression in activated and anergic T lymphocytes and GM-CSF signaling were upregulated in the frail group. These results suggest differential activation of the immune responses to vaccination in frail compared to non-frail adults.

On Day 7, eukaryotic initiation factor 2 (EIF-2) pathway showed reduced expression in the frail group compared to non-frail suggesting that a decreased protein production response may contribute to reduced immune response to influenza vaccination. This finding may be relevant, as antibody response has long been recognized as the primary aspect of immunogenicity by influenza vaccines [17, 18].

Cyclin D1 (CCND1) expression showed consistently lower expression in the frail group at all three time points, at log ratios -1.7, -1.82, and -1.83, respectively (Supplementary Table 1). These results show reduced cell proliferation in PBMCs in frail adults at Day 0, suggesting senescence in PBMC populations. Moreover, the T cell exhaustion pathway was upregulated in the frail adults on Day 0 and 7 post-vaccination. Both phenotypes are associated with immunosenescence [19].

Pathways involved in oxidative stress were upregulated in the frail group, including HIF-1α signaling, HEME biosynthesis II on Day 0, and glutathione biosynthesis on all days. Additionally, the histamine biosynthesis pathway expression, represented by histidine decarboxylase, was decreased at all three time points, at log ratios -1.44, -1.58, and -1.59 (Supplementary Table 1) on Day 0, Day 3, and Day 7, respectively. These results suggest increased oxidative stress and an alternative inflammatory state in the frail group’s PBMC populations.

Changes in DEG between Days 0 and 3 and between Days 0 and 7 in frail and non-frail groups

Vaccine-induced differences in gene expression between baseline (Day 0) and after vaccination (Day 3 or 7) were assessed. Table 5 shows significant differences in DEGs between Days 0 and 3 and between Days 0 and 7 in frail and non-frail groups. Relatively few genes were differentially expressed at 3 versus 7 days following vaccination (386 frail, 265 non-frail, Supplementary Table 2). However, the DEGs from Day 0 to either Day 3 or Day 7 differed by frailty status. Vaccination in frail patients altered gene expression in T and B cell signaling pathways and crosstalk between dendritic cells and natural killer cells. In addition, DEGs were observed in stem cell pathways. In non-frail patients DEGs were identified in oxidative stress pathways and adaptive immune activation.

Table 6 shows significant differences in DEGs between Days 0 and 7 in frail and non-frail groups (944 frail, 1252 non-frail, Supplementary Table 2). In the frail adults, genes and pathways involved in protein
Table 5. Differentially expressed pathways between Day 0 (pre-vaccination) and Day 3 post-vaccination among frail \( (N=13) \) and non-frail individuals \( (N=15) \), analyzed by Ingenuity pathways analysis.

| Ingenuity canonical pathways | Frail Day 0 – Day 3 | Non-frail Day 0 – Day 3 |
|-----------------------------|---------------------|------------------------|
|                             | Upregulated genes   | Downregulated genes    | Upregulated genes   | Downregulated genes |
| Altered T cell and B cell signaling in rheumatoid arthritis | FASLG | SPP1, TNFRSF13B, TNFRSF13C | -- | -- |
| B cell development          | --                  | --                     | -- | -- |
| Communication between innate and adaptive immune cells | -- | -- | CCL3L3, HLAG | IGHD |
| Crosstalk between dendritic cells and natural killer cells | FASLG, ITGAL, KIR3DL1, PRF1 | -- | -- | -- |
| Glutathione redox reactions I | -- | -- | GSTM1, MGST2 | -- |
| Human embryonic stem cell pluripotency | BMP8B, MRAS, PDGFRB, S1PR5, SMAD7 | WN10A, WNT16 | -- | -- |
| NAD biosynthesis II         | --                  | --                     | IDO1, MNAT3 | -- |
| Transcriptional regulatory network in embryonic stem cells | EOMES, H4C11 | H4C14 | -- | -- |

-- Pathway not significantly differentially expressed or no DEGs in category.

Table 6. Differentially expressed pathways between Day 0 (pre-vaccination) and Day 7 post-vaccination among frail \( (N=13) \) and non-frail individuals \( (N=15) \), analyzed by Ingenuity pathways analysis.

| Ingenuity canonical pathways | Frail Day 0 - Day 7 | Non-frail Day 0 - Day 7 |
|-----------------------------|---------------------|------------------------|
|                             | Upregulated genes   | Downregulated genes    | Upregulated genes   | Downregulated genes |
| Antigen presentation pathway | --                  | --                     | HLA-DPA1, HLA-    | -- |
|                             |                      |                        | DPB1, HLA-DQA1,   | AGO4, GSK3B,  |
|                             |                      |                        | HLA-DQB2, HLA-    | PIK3CG, PIK3R6 |
|                             |                      |                        | DRA, HLA-DRB1,    |                      |
|                             |                      |                        | HLA-DRB5, HLA-G,  |                      |
|                             |                      |                        | PSMB6, PSMB8      |                      |
| EIF2 signaling              | IGF1R               | EIF3C, RPL10, RPL11, RPL13A, RPL15, RPL22L1, RPL23, RPL26, RPL27, RPL29, RPL3, RPL31, RPL34, RPL35, RPL37, RPL39, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL9, RPL10, RPS13, RPS14, RPS15A, RPS17, RPS18, RPS19, RPS20, RPS21, RPS23, | AFT3, EIFAY, EIF2S2, EIF3D, EIF3E, EIF3I, EIF3K, EIF3L, EIF4A3, MT-RNR2, PAIP1, RPL10, RPL10A, RPL12, RPL13, RPL14, RPL18, RPL19, ROL21, RPL22, RPL22L1, RPL23, RPL23A, RPL24, RPL26, RPL27A, RPL29, RPL30, RPL31, RPL32, RPL34, RPL35, RPL36, RPL35A, RPL36A, RPL37, | AGO4, GSK3B, PIK3CG, PIK3R6|
|                             |                      |                        |                      |                      |
| Pathway                                      | DEGs                                                                 | DEGs                                                                 |
|---------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| NRF2-mediated oxidative stress response     | --                                                                  | --                                                                  |
| Oxidative phosphorylation                   | MT-CYB, MT-ND1, MT-ND2, MT-ND5                                      | ATP5ME, ATP5PB, COXA2, COX7B, NDUFA6, NDUFS3, UQCRQ                  |
|                                             |                                                                      | ATP5F1A, ATP5F1B, ATP5F1E, ATP5MC1, ATP5ME, ATP5MF, ATP5MG, ATP5PB, |
|                                             |                                                                      | ATP5PD, COX41, COX5A, COX5B, COX6A1, COX6B1, COX7A2, COX7C, COX8A, |
|                                             |                                                                      | CYC1, NDUFA1, NDUFA2, NDUFA3, NDUFA4, NDUFA8, NDUFB10, NDUFB2, NDUFB3, |
|                                             |                                                                      | NDUFB7, NDUFB9, NDUFS3, NDUFS5, NDUFS6, UQCR10, UQCR11, UQCRB, UQCRH, |
|                                             |                                                                      | UQCRQ                                                                |

-- Pathway not significantly differentially expressed or no DEGs in category.

production (EIF2) and energy consumption (oxidative phosphorylation) were down regulated on Day 7, compared to Day 0. In contrast, in the non-frail group these genes and pathways were upregulated. These results suggest that frailty is correlated with reduced immune cell protein production and energy generation/consumption. In addition, induction of antigen presentation pathway genes was only observed in the non-frail group.

In the frail group, 66 ribosomal protein genes were down regulated on Day 7. At the same time in the non-frail group, 80 ribosomal protein genes were upregulated on Day 7 (Supplementary Table 3). The EIF-2 pathway was down regulated post-vaccination in the frail group on Day 7 compared to Day 0, while in the non-frail group, EIF-2 was up-regulated, suggesting increased protein synthesis in the non-frail group.

In the frail group, six immunoglobulin genes were down regulated on Day 7 compared to Day 0. In contrast, in the non-frail adults, 19 immunoglobulin genes were upregulated in the same comparison (Supplementary Table 4). These findings suggest reduced antibody production, although HAI did not differ between groups. Decreased antibody production is thought to be a major aspect of decreased immune responses in the elderly, and frail adults [20].

In the frail adults, three human leukocyte antigen (HLA) genes were found to be down regulated on Day 7 compared to Day 0. By comparison, 8 MHCII genes
were upregulated in the same comparison in non-frail adults, which is expected as part of the immune responses to vaccines (Supplementary Table 5).

For an overall view of the differences between frail and non-frail groups in DEGs, three heat maps (Day 0, Day 3 and Day 7) were developed. These immune pathway heat maps show that at Day 0, genes involved in cellular movement, hematological system development and function, immune cell trafficking, cellular development, cellular growth and proliferation, and inflammatory response displayed reduced expression in the frail group compared to non-frail (Figure 1A). A similar pattern of reduced immune response genes in the frail adults can be observed on Day 3 (Figure 1B). On Day 7, genes involved in cellular movement and cellular development showed increased activities in the frail adults compared to non-frail (Figure 1C), suggesting delayed immune responses to influenza vaccination. In the frail adults, at all three time points, several gene annotations for viral infectious diseases, including replication of herpesviridae, replication of RNA virus, and replication of viral replicon, showed increased activities, presented by positive activation z-scores (>2) (Supplementary Table 6), suggesting that pre-existing infections may be more prevalent in this group.

DISCUSSION

Immunosenescence, chronically high levels of circulating inflammatory cytokines (inflammaging), and the overall declines evident in both innate and adaptive immunity that come with aging reduce vaccination responses in older adults [21, 22]. Other factors associated with aging may also reduce the effectiveness of vaccines among older adults. Physical frailty a common, but not universal correlate of advancing age, [23, 10] is one such factor that may further attenuate immune response to vaccines. Recent studies have not demonstrated significant differences in post-influenza vaccination antibody response between frail and non-frail adults ≥65 years [9–12]. The current study confirms previous research; however, significant differences in PBMCs were evident between frail and non-frail groups suggesting differences in the degree of cell-mediated immunity (CMI) activation.

We found many differences in gene expression of PBMCs between the frail and non-frail groups. The T cell exhaustion pathway in frail adults was upregulated

![Figure 1. Heat maps comparing frail to non-frail on day 0 (A), day 3 (B), and day 7 (C) post-vaccination. Lower expression of genes involved in cellular movement, hematological development and function, immune cell trafficking, and inflammatory response can be observed in the frail group compared with non-frail on day 0 and day 3. Higher expression of genes involved cellular movement, cell-to-cell signaling and interaction, and cellular development is shown in the frail group compared with non-frail on day 7. Genes involved in infectious diseases were consistently expressed at higher levels in frail versus non-frail adults at all three time points.](image-url)
on Day 0 and 7 post-vaccination compared to the non-frail adults. T cell exhaustion, particularly programmed cell death protein 1 (PD1) and its ligands PDL1/2 signaling have been widely studied in tumor immunotherapies [24]. Recent studies have shown that increased PD1 expression was associated with more severe influenza infection [25], and blockade of the PD1/PDL1 axis enhanced influenza viral clearance in mice [26]. Trivalent inactivated vaccine did not induce immune-related adverse events in cancer patients receiving PD-1 therapies [27, 28], and PD-1 treatment was associated with rapid increase of seral conversion among cancer patients, when compared with healthy controls, and cancer patients undergoing cytotoxic chemotherapy [28]. Our results suggest that T cell exhaustion after influenza vaccination is a phenotype of adult frailty. PD-1 blockade therapy aiming to reduce T cell exhaustion may prove effective in boosting vaccine responses in frail adults.

Expression of several interferon-inducible anti-viral genes including IFIT1 [29–31], interferon-inducible human oligoadenylate synthetase family (OAS) proteins OAS1, OAS2, and OAS-like protein [32, 33], viperin [34], interferon stimulated exonuclease gene 20 (ISG20) [35], and MX1 [36] were expressed at consistently lower levels in frail adults. Competent interferon signaling has been recognized as a critical response to influenza vaccines [37, 38] and to mount an effective host defense against influenza infection [39, 40]. The impact of aging and frailty on interferon signaling is unclear. IFIT1, IFIT3 [41], IFITM3 [29], MX1 [42], and ISG15 [43] have all been shown to possess anti-influenza activities; however, a genetic variant of IFITM3 has been associated with severe influenza infection and higher hospitalization rate [30, 44]. Wild type mice treated with exogenous interferon had a higher survival rate and lower viral titers compared to MX1 −/− mice after influenza A/H1N1 and A/H5N1 infections [42, 45]. Another study found MX1 was protective against influenza A/H1N1 in mice and discovered reduced monocyte interferon-β expression in aged human subjects [46]. We observed reduced interferon signaling in frail adults at Days 0, 3, and 7 post-vaccination. Our results suggest that increasing type-1 interferon signaling may provide therapeutic targets for influenza treatment in the elderly, and for developing influenza vaccine adjuvants.

Previous studies have suggested repeated cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infections, both of which are in the family of herpesviridae, may contribute to immunosenescence and reduced immunogenicity of influenza vaccination [47–50]. Chronic infection with CMV and EB virus have been associated with frailty, and have been recognized as potential factors causing immunosenescence [47, 49, 51]. CMV in particular causes “memory inflation” in CD8+ cells, meaning repeated infection with different types of CMV causes expansion of antigen-specific CD8+ cells reactive to specific CMV strains’ proteins. These CMV-specific populations can take up as much as 50% of the peripheral CD8+ cell and 30% of CD4+ cell repertoire [51], greatly affecting cellular immune responses. Our DEG analyses showed consistent increased gene annotations for herpesviridae infection in frail adults on Days 0, 3, and 7 post-vaccination. In addition to herpesviruses, RNA virus replication was shown to be increased in the frail adults, whereas interferon-associated, anti-viral gene expression was lower compared to the non-frail adults, suggesting reduced immunity against viral infections.

We observed reduced transcripts for ribosomal proteins in frail adults at Day 7 post-vaccination. In contrast, non-frail adults increased ribosomal protein gene expression at Day 7. Ribosome concentration is positively correlated with mRNA translational output [52]. Inhibition of ribosome synthesis was associated with increased CMV infection [53]. Others have found in proteomics analysis, reduced skeletal muscle ribosomal protein levels associated with aging [54]. Our results did not differentiate gene expression by cell types. Further studies using single cell sequencing are needed to provide a clearer picture of how aberrant ribosomal protein expression can affect immune responses to influenza vaccination in the elderly, whether by affecting antibody production, or by affecting HLA assembly, expression, antigen processing or presentation.

We also observed concurrent changes in ribosomal protein pseudogenes expression with ribosomal proteins. There have been more than 2000 ribosomal protein pseudogenes described in the literature [55, 56]. The increase in both ribosomal protein and pseudogenes could be due to shared transcription factors, and others have suggested that some ribosomal protein pseudogenes may indeed have protein-coding functions [56, 57].

Mitochondrial dysfunction and reduced mitochondrial content have been suggested as a cause for accelerated frailty [58, 59]. In the frail group, we observed decreased oxidative phosphorylation on Day 7 compared to Day 0, in contrast to the non-frail group in which oxidative phosphorylation gene expression increased from Day 0 to Day 7. mTOR signaling was also reduced in the frail group on Day 7 compared to non-frail group (data not shown). These changes suggest the frail group had reduced energy production/consumption on Day 7 post-vaccination.
Oxidative stress has long been suggested as a mechanism of aging. Increased oxidative stress and altered redox balance have been shown to be associated with frailty [60]. Consistent with these previous studies, our results show that frail adults had increased expression of oxidative pathways, such as heme, *HIF1α*, and glutathione biosynthesis. To our knowledge, our study is the first to link the PBMC transcriptome to frailty, whereas previous studies focused on oxidized plasma proteins/lipids using immunoblots or analytical chemistry methods [61], genomic SNP variations, or epigenetic modification of DNA methylation [62, 63]. Our study provides important insights into oxidative stress pathways in frail adults and may provide therapeutic targets for reducing oxidative stress.

**Strengths and limitations**

This was a racially diverse cohort with varying levels of frailty, whose living situation ranged from community-dwelling to long-term care facilities,. We were unable to collect PBMCs from the entire cohort. However, the differences observed between frail and non-frail groups were robust. In the PBMC study, frail and non-frail groups differed by age, with the frail patients being older. Some of the differences found may be related to aging, although corrections for age were made in differential analyses.

Our RNAseq results were only aligned with human genes, thus we have limited information on specific viral infections affecting the subjects’ PBMC populations. It would be interesting to determine if antiviral medications for treatments of other types of herpesviruses, such as herpes simplex 1 and 2, and varicella zoster, can affect T cell populations and immunosenescence.

**CONCLUSIONS**

This study has identified a number of differences in immune response to influenza vaccination between frail and non-frail older adults. Compared with non-frail older adults, frail adults had reduced expression of genes required for cell proliferation, protein translation, metabolism, antibody production, and interferon expression. The frail group also displayed increased expression of oxidative stress, *IL-8* signaling, and T cell exhaustion genes indicative of immunosenescence. These data shed light on altered transcriptional programs in PBMCs in frail, older adults which are present even in the absence of changes in antibody titers and may contribute to the design of new influenza vaccines. Furthermore, HAI titers may not be the most appropriate assessment of immune response to influenza vaccination among older adults.

**MATERIALS AND METHODS**

**Study design and participants**

This study was an observational prospective study of immune response to the 2017-2018 influenza vaccine. Participants ≥55 years of age were recruited from primary care practices, the community, and senior living facilities in the fall of 2017, using nonprobability convenience sampling. Eligibility included at least one prior season’s receipt of influenza vaccine, no known allergies to the vaccine or vaccine components, and intention to receive the 2017-2018 influenza vaccine. Participants were ineligible if they had a life expectancy of <6 months, a severe allergy to influenza vaccine or to eggs, a history of Guillain-Barré syndrome, a current immunosuppressive condition or an expected immunosuppressive condition within 6 months, use of immunosuppressant medications, or a history of allograft transplant. The University of Pittsburgh and Centers for Disease Control and Prevention Institutional Review Boards (IRB) approved this study and all participants provided written informed consent prior to initiating study procedures.

**Baseline data collection**

Baseline data were collected either by interview, written survey or electronic data retrieval from the electronic medical record (EMR). Demographics included age, sex, race, ethnicity, educational status, smoking status, presence (yes/no) of chronic health conditions, use (yes/no) and name of statin medication. Height and weight were used to calculate Body Mass Index (BMI). BMI was calculated as [weight (lb.) ÷ (height (in.)² X 703)]; categorical obesity was defined as BMI ≥30. Functional disability status was assessed using the activities of daily living (ADL) and instrumental activities of daily living (IADL) questionnaires (scores range from 0=low functionality to 14=high functionality). Physical frailty was assessed at baseline using the 5 components outlined in Fried et al.’s Physical Frailty Phenotype [7]. Performance-based components included gait speed (slowness) and hand-grip strength (weakness). Questionnaire-based components included unintentional weight loss ≥10 lbs. in the last year (weight loss), 2-questions from the CES-D Depression scale based on the past week (exhaustion) and 18 activities from the short-version of the Minnesota Leisure Time Activity Questionnaire based on the past 2 weeks. Individual components were either gender-adjusted to specified cut points or adjusted according to specified calculations noted by Fried et al. [7] to determine the frailty score for each component (0=non-frail; 1=frail). Components were then summed (range=0-5). Participants were determined to be frail if
they had ≥2 “frail” components and non-frail if they had ≤1 “frail” component.

Biological samples

Non-fasting whole blood samples were obtained from all participants at Day 0 (pre-vaccination) and 28 (range 19-35) days post influenza vaccination into BD Vacutainer™ serum separator tubes with polymer gel/silica activator additive (BD 367985) for serum HAI determinations and into BD Vacutainer™ CPT™ mononuclear cell preparation tubes with sodium citrate additive (BD 362761) for serum peripheral blood mononuclear cells (PBMCs) on Days 0, 3 (range=3-4) and 7 (range= 6-10) PBMCs were collected for a subgroup of participants who agreed to the additional blood draws and from whom these samples could be obtained. All tubes were held at room temperature and delivered to the processing laboratory within 4 hours of draw. Aliquotted serum samples were frozen at -80°C until assayed.

Influenza vaccine

Following the Day 0 blood draw, all participants received an intramuscular injection of either the high dose or standard dose seasonal 2017-2018 inactivated influenza vaccine. The trivalent high dose vaccine contained the A/H1N1/Michigan/45/2015-pdm09-like virus, A/H3N2/Hong Kong/4801/2014-like virus and B/Brisbane/60/2008-like influenza virus. The quadrivalent standard dose vaccine also contained the B/Phuket/3073/2013-like virus.

HAI processing and analysis

Antibody assays were conducted following CDC’s protocols [64] by the Influenza Division research laboratory at CDC, who were blinded to group assignment. Sera were heat inactivated, tested for nonspecific agglutinins, and adsorbed as needed, then serially diluted 2-fold and incubated with 4 hemagglutination units per 25μL of virus with erythrocytes for quantification of HAI titers. Turkey erythrocytes were used for the testing of A/H1N1 viruses. HAI titer was defined as the reciprocal of the last dilution of serum that completely inhibited hemagglutination. Antibody titers <10 (initial sera dilution) were reported as 5 for analysis. Sera were tested in HAI assays against the A/H1N1 vaccine strain included in the 2017-2018 influenza vaccine (A/Michigan/45/2015).

Primary outcome measures were seropositivity at Day 28 and seroconversion of antibodies to influenza A/H1N1. Seropositivity was defined as a HAI titer ≥1:40 at Day 0 and at Day 28. Seroconversion was defined as a 4-fold rise in HAI titer post-vaccination given a pre-vaccination titer ≥10. Secondary outcome measures were log₂ Day 28 HAI titers and fold-rise in log₂ HAI titers from Day 0 to Day 28 defined as the ratio of log₂ Day 28 to log₂ Day 0 titers.

PBMC processing and analysis

PBMCs were isolated from serum drawn into CPT™ mononuclear cell preparation tubes with sodium citrate additive (BD 362761) following the manufacturer’s protocol. After isolation, PBMCs were lysed in RLT buffer (Qiagen) and stored at -80°C for RNA isolation using RNeasy kit (Qiagen). Total RNA from PBMCs was isolated from collections at Days 0, 3 and 7 post-vaccination; ribosomal RNA was depleted (Ribo-zero Gold) and sequenced using the Illumina TruSeq platform. Reads per sample were collected and mapped to the Human Ensembl reference genome GRCh38 using the fast alignment tool HISAT2 v2.1.0. EdgeR v3.26.8, an R Bioconductor package, was used for differential gene analysis comparing various sample groups with a gene expression filter of >1 copy per million (CPM) in at least three samples in a given group. Pathway analyses were performed using Ingenuity Pathway Analysis tools (Qiagen). All sequencing data will be provided to GEO Datasets upon publication.

Statistical analyses

Summary statistics of demographics and immunological response outcomes were conducted for all participants and for the PBMC subgroup by frailty status using Chi-square/Fisher’s exact tests for categorical variables and Wilcoxon/t-tests for continuous variables. Proportions are reported for categorical variables and means and standard deviations or median and quartiles 1 and 3 are reported for continuous variables. Due to the skewness of the HAI titers, they were transformed using the log₂ function at each timepoint.

The association between frailty and HAI antibody response to influenza vaccine was examined using logistic regression (seroconversion and seropositivity) and linear regression (log₂ transformed Day 28 antibody titers and fold-rise in log₂ antibody titers). Analyses were conducted for the entire cohort but not for the PBMC subgroup because sample sizes were inadequate for these analyses. Multivariable regression models included covariates that were significant in univariable analyses (P < 0.20) for any outcome measure. Frailty was included a priori. Due to the high level of correlation between independent covariates, multivariable stepwise forward regression models were
run with $P \leq 0.10$ to enter and $P \leq 0.05$ to stay. Statistical significance of two-sided tests was set at type I error (alpha) = 0.05. These analytical procedures were performed using SAS® 9.3 (Cary, NC).

Paired sample analysis (Day 0 to Day 3 or Day 0 to Day 7) was completed using the edgeR function glmFit after normalization of gene counts controlling for age in the model matrix. The false discovery rate (FDR) for each gene was calculated using the Benjamini-Hochberg method because of the multiple null hypotheses being tested. A generalized linear model was used to test for differences in gene expression due to age by performing a likelihood-ratio test with age selected as an adjustment factor [65].

AUTHOR CONTRIBUTIONS

Dr. Zimmerman, Dr. Nowalk, Dr. Nace and Dr. Alcorn conceived the study design. Dr. Moehling and Mr. Susick helped collect the demographic and frailty data and blood specimens. Dr. Zhai, Dr. Levine and Ms. Ortiz performed laboratory analyses. Dr Chandran and Mr. Schwarzman analyzed the RNA data. Dr. Moehling and Dr. Lin, analyzed the antibody and demographic data. Dr. Moehling, Dr. Zhai, Dr. Nowalk, Dr. Alcorn, Dr. Levine, Dr. Nace and Dr. Zimmerman drafted and edited the manuscript. All authors read and approved the manuscript.

CONFLICTS OF INTEREST

Drs. Lin and Zimmerman report grant funding from Sanofi Pasteur and Merck & Co., Inc. Dr. Nowalk reports grant funding from Merck & Co., Inc. The other authors, Dr. Moehling, Dr. Zhai, Mr. Schwarzmann, Mr. Susick, Ms. Ortiz, Dr. Alcorn, Dr. Nace, Dr. Chandran report no conflicts of interest.

FUNDING

This work was supported by the Centers for Disease Control and Prevention (CDC)U01 IP001035. Additional support came from the National Institutes of Health (NIH) UL1 TR001857 (RKK), T32 HL129949 (BZ) and T32 Health Research Services Administration (HRSA) under Award Number T32HP22240 (KM). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC, the NIH or HRSA.

REFERENCES

1. Centers for Disease Control and prevention. Influenza (Flu). Background and Epidemiology https://www.cdc.gov/flu/professionals/acip/backgrou

2. Pilkinton MA, Talbot HK. Update on vaccination guidelines for older adults. J Am Geriatr Soc. 2015; 63:584–88. https://doi.org/10.1111/jgs.13375 PMID:25753174

3. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev. 2011; 10:379–88. https://doi.org/10.1016/j.arr.2010.10.008 PMID:21055484

4. Gruver AL, Hudson LL, Sempowski GD. Immunosenesence of ageing. J Pathol. 2007; 211:144–56. https://doi.org/10.1002/path.2104 PMID:17200946

5. Espinoza S, Walston JD. Frailty in older adults: insights and interventions. Cleve Clin J Med. 2005; 72:1105–12. https://doi.org/10.3949/ccjm.72.12.1105 PMID:16392724

6. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013; 14:392–97. https://doi.org/10.1016/j.jamda.2013.03.022 PMID:23764209

7. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, and Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56:M146–56. https://doi.org/10.1093/gerona/56.3.m146 PMID:11253156

8. Yao X, Hamilton RG, Weng NP, Xue QL, Bream JH, Li H, Tian J, Yeh SH, Resnick B, Xu X, Walston J, Fried LP, Leng SX. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011; 29:5015–21. https://doi.org/10.1016/j.vaccine.2011.04.077 PMID:21565245

9. Bauer JM, De Castro A, Bosco N, Romagny C, Diekmann R, Benyacoub J, Vidal K. Influenza vaccine response in community-dwelling German prefrail and frail individuals. Immun Ageing. 2017; 14:17. https://doi.org/10.1186/s12979-017-0098-z PMID:28694834

10. Moehling KK, Nowalk MP, Lin CJ, Bertolet M, Ross TM, Carter CE, Susick M, Saul SG, Kaynar AM, Bromberger JT, Zimmerman RK. The effect of frailty on HAI response to influenza vaccine among community-
1. Ovsyannikova IH, Painter SD, Kennedy RB, Ovsyannikova IG, Lambert ND, Goergen KM, Oberg AL, Poland GA. The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects. PLoS One. 2015; 10:e0122282. https://doi.org/10.1371/journal.pone.0122282 PMID:25816015

2. Van Epps P, Tumpey T, Pearce MB, Golden H, Higgins P, Hornick T, Burant C, Wilson BM, Banks R, Gravenstein S, Canaday DH. Preexisting immunity, not frailty phenotype, predicts influenza postvaccination titers among older veterans. Clin Vaccine Immunol. 2017; 24:e00498–16. https://doi.org/10.1128/CVI.00498-16 PMID:28100496

3. McElhaney JE, Del Giudice G, Effros RB, Grubeck-Loebeinstein B, Sahmara S. Challenges for vaccination in the elderly. Immun Ageing. 2007; 4:9. https://doi.org/10.1186/1742-4933-4-9 PMID:18072962

4. Van Epps P, Tumpey T, Pearce MB, Golden H, Higgins P, Hornick T, Burant C, Wilson BM, Banks R, Gravenstein S, Canaday DH. Preexisting immunity, not frailty phenotype, predicts influenza postvaccination titers among older veterans. Clin Vaccine Immunol. 2017; 24:e00498–16. https://doi.org/10.1128/CVI.00498-16 PMID:28100496

5. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Zimmermann MT, Haralambieva IH, Goergen KM, Grill DE, Poland GA. Gene signatures associated with adaptive humoral immunity following seasonal influenza A/H1N1 vaccination. Genes Immun. 2016; 17:371–79. https://doi.org/10.1038/gene.2016.34 PMID:27534615

6. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972; 70:767–77. https://doi.org/10.1017/s0022172400022610 PMID:4509641

7. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006; 24:1159–69. https://doi.org/10.1016/j.vaccine.2005.08.105 PMID:16213065

8. Lorenzo EC, Bartley JM, Haynes L. The impact of aging on CD4+ T cell responses to influenza infection. Biogerontology. 2018; 19:437–46. https://doi.org/10.1007/s10522-018-9754-8 PMID:29616390

9. van den Berg SP, Wong A, Hendriks M, Jacobi RH, van Baarle D, van Beek J. Negative effect of age, but not of latent cytomegalovirus infection on the antibody response to a novel influenza vaccine strain in healthy adults. Front Immunol. 2018; 9:82. https://doi.org/10.3389/fimmu.2018.00082 PMID:29434600

10. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebeinstein B, Sahmara S. Challenges for vaccination in the elderly. Immun Ageing. 2007; 4:9. https://doi.org/10.1186/1742-4933-4-9 PMID:18072962

11. Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012; 60:1487–92. https://doi.org/10.1111/j.1532-5415.2012.04054.x PMID:22881367

12. Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019; 10:2965. https://doi.org/10.3389/fimmu.2019.02965 PMID:31921205

13. Rutigliano JA, Sharma S, Morris MY, Oguin TH 3rd, McClaren JL, Doherty PC, Thomas PG. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J Virol. 2014; 88:1636–51. https://doi.org/10.1128/JVI.02851-13 PMID:24257598

14. McNally B, Ye F, Willette M, Fláñio E. Local blockade of epithelial PDL-1 in the airways enhances T cell function.
and viral clearance during influenza virus infection. J Virol. 2013; 87:12916–24. 
https://doi.org/10.1128/JVI.02423-13
PMID: 24067957

27. Wijn DH, Groeneveld GH, Vollaard AM, Muller M, Wallinga J, Gelderblom H, Smit EF. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer. 2018; 104:182–187. 
https://doi.org/10.1016/j.ejca.2018.09.012
PMID: 30368069

28. Läubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, Hertig A, Müller B, Gautschi O, Stenner F, Zippelius A, Egli A, Rothschild SI. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. J Immunother Cancer. 2018; 6:40. 
https://doi.org/10.1186/s40425-018-0353-7
PMID: 29789020

29. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, et al, and GenISIS Investigators, and MOSAIC Investigators. IFITM3 restricts the morbidity and mortality associated with influenza. Nature. 2012; 484:519–23. 
https://doi.org/10.1038/nature10921 PMID: 22446288

30. Allen EK, Randolph AG, Bhangale T, Dogra P, Ohlson M, Oshansky CM, Zamora AE, Shannon JP, Finkelstein D, Dressen A, DeVincenzo J, Caniza M, Youngblood B, et al. SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans. Nat Med. 2017; 23:975–83. 
https://doi.org/10.1038/nm.4370 PMID: 28714988

31. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. The IFITM proteins mediate cellular resistance to influenza a H1N1 virus, West Nile virus, and dengue virus. Cell. 2009; 139:1243–54. 
https://doi.org/10.1016/j.cell.2009.12.017 PMID: 20064371

32. Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, Behl B, Parise RA, Beumer JH, O’Sullivan RJ, DeLuca NA, Thorne SH, Rathinam VA, et al. Oligoadenylate-synthetase-family protein OASL inhibits activity of the DNA sensor cGAS during DNA virus infection to limit interferon production. Immunity. 2019; 50:51–63.e5. 
https://doi.org/10.1016/j.immuni.2018.12.013 PMID: 30635239

33. Choi UY, Kang JS, Hwang YS, Kim YJ. Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases. Exp Mol Med. 2015; 47:e144. 
https://doi.org/10.1038/emm.2014.110 PMID: 25744296

34. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci USA. 2001; 98:15125–30. 
https://doi.org/10.1073/pnas.011593298 PMID: 11752458

35. Espert L, Degols G, Gongora C, Blondel D, Williams BR, Silverman RH, Mechi N. ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomivs. J Biol Chem. 2003; 278:16151–58. 
https://doi.org/10.1074/jbc.M209628200 PMID: 12594219

36. Dittmann J, Stertz S, Grimm D, Steel J, García-Sastre A, Haller O, Kochs G. Influenza A virus strains differ in sensitivity to the antiviral action of mx-GTPase. J Virol. 2008; 82:3624–31. 
https://doi.org/10.1128/JVI.01753-07 PMID: 18199636

37. Du Y, Xin L, Shi Y, Zhang TH, Wu NC, Dai L, Gong D, Brar G, Shu S, Luo J, Reiley W, Tseng YW, Bai H, et al. Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design. Science. 2018; 359:90–96. 
https://doi.org/10.1126/science.aan8806 PMID: 29348231

38. Cao RG, Suarez NM, Obermoser G, Lopez SM, Flano E, Mertz SE, Albrecht RA, García-Sastre A, Mejias A, Xu H, Qin H, Blankenship D, Palucka K, et al. Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine. Proc Natl Acad Sci USA. 2003; 100:1977–82. 
https://doi.org/10.1073/pnas.011593298 PMID: 11752458

39. Teijaro JR, Burton DR. Taking down defenses to improve vaccines. Science. 2018; 359:277–78. 
https://doi.org/10.1126/science.aar5421 PMID: 29348225

40. Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019; 23:303. 
https://doi.org/10.1186/s13054-019-2566-7 PMID: 31488196

41. Schmeisser A, Mejido J, Balinsky I, Morrow AN, Clark CR, Zhao T, Zoon KC. Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene. J Virol. 2010; 84:10671–80. 
https://doi.org/10.1128/JVI.00818-10 PMID: 20686046

42. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martínez-
Influenza vaccine-mediated protection in older adults: impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. 2018; 107:116–25. https://doi.org/10.1016/j.exger.2017.09.015 PMID:28958701

51. Tu W, Rao S. Mechanisms underlying T cell immunosenescence: aging and cytomegalovirus infection. Front Microbiol. 2016; 7:2111. https://doi.org/10.3389/fmicb.2016.02111 PMID:28082969

52. Mills EW, Green R. Ribosomopathies: there’s strength in numbers. Science. 2017; 358:eaan2755. https://doi.org/10.1126/science.aan2755 PMID:29097519

53. Bianco C, Mohr I. Ribosome biogenesis restricts innate immune responses to virus infection and DNA. Elife. 2019; 8:e49551. https://doi.org/10.7554/elife.49551 PMID:31841110

54. Ubaida-Mohien C, Lyashkov A, Gonzalez-Freire M, Tharakan R, Shardell M, Moaddel R, Semba RD, Chia CW, Gorospe M, Sen R, Ferrucci L. Discovery proteomics in aging human skeletal muscle finds change in spliceosome, immunity, proteostasis and mitochondria. Elife. 2019; 8:e49874. https://doi.org/10.7554/elife.49874 PMID:31642809

55. Zhang Z, Harrison P, Gerstein M. Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res. 2002; 12:1466–82. https://doi.org/10.1101/gr.331902 PMID:12368239

56. Tonner P, Srinivasasainagendra V, Zhang S, Zhi D. Detecting transcription of ribosomal protein pseudogenes in diverse human tissues from RNA-seq data. BMC Genomics. 2012; 13:412. https://doi.org/10.1186/1471-2164-13-412 PMID:22908856

57. Balasubramanian S, Zheng D, Liu YJ, Fang G, Frankish A, Carriero N, Robilotto R, Cayting P, Gerstein M. Comparative analysis of processed ribosomal protein pseudogenes in four mammalian genomes. Genome Biol. 2009; 10:R2. https://doi.org/10.1186/gb-2009-10-1-r2 PMID:19123937

58. Ferrucci L, Zampino M. A mitochondrial root to accelerated ageing and frailty. Nat Rev Endocrinol. 2020; 16:133–4. https://doi.org/10.1038/s41574-020-0319-y PMID:31992872

59. Sonjak V, Jacob KJ, Spendiff S, Vuda M, Perez A, Miguez K, Minozzo FC, Spake C, Morais JA, Hepple RT. Reduced mitochondrial content, elevated reactive oxygen species, and modulation by denervation in skeletal muscle. Aging Cell. 2010; 9:647–58. https://doi.org/10.1111/j.1474-9726.2010.00558.x PMID:20706082

43. Morales DJ, Lenschow DJ. The antiviral activities of ISG15. J Mol Biol. 2013; 425:4995–5008. https://doi.org/10.1016/j.jmb.2013.09.041 PMID:24095857

44. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E, Jin RH, Yan HP, Wu H, Liu JH, Liu N, Wang DY, Shu YL, Ho LP, et al. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun. 2013; 4:1418. https://doi.org/10.1038/ncomms2433 PMID:23361009

45. Tumpey TM, Szretter KJ, Van Hoeven N, Katz JM, Kochs G, Haller O, Garcia-Sastre A, Staeheli P. The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol. 2007; 81:10818–21. https://doi.org/10.1128/JVI.01116-07 PMID:17652381

46. Pillai PS, Molony RD, Martinod K, Dong H, Pang IK, Tal MC, Solis AG, Bielecki P, Mohanty S, Trentalange M, Homer RJ, Flavell RA, Wagner DD, et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science. 2016; 352:463–66. https://doi.org/10.1126/science.aaf3926 PMID:27102485

47. Thomasini RL, Pereira DS, Pereira FSM, Mateo EC, Mota TN, Guimarães GG, Pereira LSM, Lima CX, Teixeira MM, Teixeira AL Junior. Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS One. 2017; 12:e0180841. https://doi.org/10.1371/journal.pone.0180841 PMID:28700679

48. Kleinerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016; 16:367–77. https://doi.org/10.1038/nri.2016.38 PMID:27108521

49. Araújo Carvalho AC, Tavares Mendes ML, Santos VS, Tanajura DM, Prado Nunes MA, Martins-Filho PR. Association between human herpes virus seropositivity and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2018; 48:145–52. https://doi.org/10.1016/j.arr.2018.10.009 PMID:30391341

50. Merani S, Kuchel GA, Kleppinger A, McElhaney JE.
60. Viña J, Borras C, Gomez-Cabrera MC. A free radical theory of frailty. Free Radic Biol Med. 2018; 124:358–363. 
https://doi.org/10.1016/j.freeradbiomed.2018.06.028  
PMID: 29958933

61. Liu CK, Lyass A, Larson MG, Massaro JM, Wang N, D’Agostino RB Sr, Benjamin EJ, Murabito JM. Biomarkers of oxidative stress are associated with frailty: the Framingham offspring study. Age (Dordr). 2016; 38:1. 
https://doi.org/10.1007/s11357-015-9864-z  
PMID: 26695510

62. Sánchez-Flores M, Marcos-Pérez D, Costa S, Teixeira JP, Bonassi S, Pástor E, Laffon B, Valdiglesias V. Oxidative stress, genomic features and DNA repair in frail elderly: a systematic review. Ageing Res Rev. 2017; 37:1–15. 
https://doi.org/10.1016/j.arr.2017.05.001  
PMID: 28487242

63. Lei W, Xu Y, Su J, Chong CM, SuHX, Luo J, Fang EF, Bao Z, Chen G. Applications of high-throughput ‘omics’ data in the study of frailty. Transl Med Aging. 2019; 3:40–51.

64. WHO Global Influenza Surveillance Network. Serological diagnosis of influenza by haemagglutination inhibition testing. In: Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva, Switzerland: WHO; 2011. 
https://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance_influenza/en/

65. Chen Y, McCarthy D, Robinson M, Smyth GK. edgeR: differential expression analysis of digital gene expression data. User’s Guide. 2020 
http://www.bioconductor.org/packages/release/bioc/vignettes/edgeR/inst/doc/edgeRUsersGuide.pdf
**SUPPLEMENTARY MATERIALS**

**Supplementary Tables**

Please browse Full Text version to see the data of Supplementary Tables 1, 2, 3, 6.

**Supplementary Table 1.** All differentially expressed genes between non-frail and frail patients on days 0, 3, and 7.

**Supplementary Table 2.** All differentially expressed genes between days 0 and 3 or 7 in frail and non-frail patients.

**Supplementary Table 3.** Differentially expressed ribosomal protein genes in frail and non-frail patients.

**Supplementary Table 4.** Differentially expressed immunoglobulin genes in frail and non-frail patients.

| Day 0 - 7 Non-frail | Symbol | Entrez gene name | Expr fold change |
|---------------------|--------|------------------|-----------------|
| IGHD                | immunoglobulin heavy constant delta | -1.235 |
| IGHG1               | immunoglobulin heavy constant gamma 1 (G1m marker) | 2.06 |
| IGHG3               | immunoglobulin heavy constant gamma 3 (G3m marker) | 1.3 |
| IGHGP               | immunoglobulin heavy constant gamma P (non-functional) | 1.51 |
| IGHV1-69            | immunoglobulin heavy variable 1-69 | -2.128 |
| IGHV4-39            | immunoglobulin heavy variable 4-39 | 1.24 |
| IGKC                | immunoglobulin kappa constant | 1.28 |
| IGKV1-6            | immunoglobulin kappa variable 1-6 | 1.79 |
| IGKV1-12           | immunoglobulin kappa variable 1-12 | 1.57 |
| IGKV1-16           | immunoglobulin kappa variable 1-16 | 1.45 |
| IGKV1-17           | immunoglobulin kappa variable 1-17 | 1.42 |
| IGKV1-33           | immunoglobulin kappa variable 1-33 | 1.26 |
| IGKV1-39           | immunoglobulin kappa variable 1-39 (gene/pseudogene) | 1.31 |
| IGKV2-28           | immunoglobulin kappa variable 2-28 | 2.21 |
| IGKV3-20           | immunoglobulin kappa variable 3-20 | 1.43 |
| IGLC2              | immunoglobulin lambda constant 2 | 1.24 |
| IGLC3              | immunoglobulin lambda constant 3 (Kern-Oz+ marker) | 1.32 |
| IGLV1-40           | immunoglobulin lambda variable 1-40 | 1.41 |
| IGLV1-44           | immunoglobulin lambda variable 1-44 | 1.5 |
| IGLV2-11           | immunoglobulin lambda variable 2-11 | 1.37 |
| IGLV3-21           | immunoglobulin lambda variable 3-21 | 1.7 |

| Day 0 - 7 Frail | Symbol | Entrez gene name | Expr fold change |
|----------------|--------|------------------|-----------------|
| IGHV1-69D      | immunoglobulin heavy variable 1-69D | -1.493 |
| IGKV2-24       | immunoglobulin kappa variable 2-24 | -3.226 |
| IGKV2D-29      | immunoglobulin kappa variable 2D-29 | -1.754 |
| IGKV3-15       | immunoglobulin kappa variable 3-15 | -1.389 |
| IGLL1/IGLL5    | immunoglobulin lambda like polypeptide 5 | -1.333 |
| IGLV3-19       | immunoglobulin lambda variable 3-19 | -1.538 |
### Supplementary Table 5. Differentially expressed human leukocyte antigen genes in frail and non-frail patients.

| Day 0 - 7 Non-frail | Entrez gene name | Expr fold change |
|---------------------|------------------|------------------|
| HLA-DPA1            | major histocompatibility complex, class II, DP alpha 1 | 1.13             |
| HLA-DPB1            | major histocompatibility complex, class II, DP beta 1  | 1.14             |
| HLA-DQA1            | major histocompatibility complex, class II, DQ alpha 1 | 1.12             |
| HLA-DQB2            | major histocompatibility complex, class II, DQ beta 2  | 1.34             |
| HLA-DRA             | major histocompatibility complex, class II, DR alpha  | 1.23             |
| HLA-DRB1            | major histocompatibility complex, class II, DR beta 1 | 1.16             |
| HLA-DRB5            | major histocompatibility complex, class II, DR beta 5 | 1.18             |
| HLA-G               | major histocompatibility complex, class I, G           | 1.33             |
| HLA-W               | major histocompatibility complex, class I, W (pseudogene) | -1.235          |

| Day 0 - 7 Frail     | Entrez gene name | Expr fold change |
|---------------------|------------------|------------------|
| HLA-DRA             | major histocompatibility complex, class II, DR alpha  | -1.176           |
| HLA-G               | major histocompatibility complex, class I, G           | -1.389           |
| HLA-J               | major histocompatibility complex, class I, J (pseudogene) | -1.299          |

### Supplementary Table 6. Significantly altered gene expression pathways that correspond to Figure 1 heatmaps.